Reuters logo
10 months ago
BRIEF-Bavarian Nordic starts Phase 2 combination trial of PROSTVAC and Ipilimumab
October 10, 2016 / 11:06 AM / 10 months ago

BRIEF-Bavarian Nordic starts Phase 2 combination trial of PROSTVAC and Ipilimumab

Oct 10 (Reuters) - Bavarian Nordic A/S

* Announces initiation of Phase 2 combination trial of PROSTVAC and Ipilimumab in patients with localized prostate cancer

* Primary endpoint of study is to evaluate CD3+ T cell immune responses and secondary measures include immunologic infiltration, circulating effector T cells and regulatory T cells Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below